<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02656147</url>
  </required_header>
  <id_info>
    <org_study_id>Doing-004</org_study_id>
    <nct_id>NCT02656147</nct_id>
  </id_info>
  <brief_title>Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL</brief_title>
  <official_title>Phase I Study of γδT Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Doing Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Doing Biomedical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric
      Antigen Receptor (CAR) redirected allogeneic γδT-cells in patients with high risk, relapsed
      CD19+ haematological malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-centre, non-randomised, open label Phase I clinical trial of an Advanced
      Therapy Investigational Medicinal Product named CD19 Chimeric Antigen Receptor (CAR)
      γδT-cells (CD19 CAR γδT-cells) in patients with high risk, relapsed CD19+ haematological
      malignancies (Leukemia and lymphoma). Following informed consent and registration to the
      trial, Patients will receive the allogeneic CD19 CAR γδT-cells following lymphodepleting
      chemotherapy. The study will evaluate the safety, efficacy and duration of response of the
      CD19 CAR γδT-cells in patients with high risk relapsed CD19+ malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2017</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events of each patient.</measure>
    <time_frame>3 years</time_frame>
    <description>Adverse events of each patient will be recorded and analysed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival time of Anti-CD19 CAR γδT cells in vivo.</measure>
    <time_frame>3 years</time_frame>
    <description>PCR will be applied to analyse the survival time of Anti-CD19 CAR γδT cells in vivo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor Effects</measure>
    <time_frame>Every 3 months post treatment up to 24 months</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum tolerated dose (MTD) of CD19 targeted CAR γδT cells.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) of CD19 targeted CAR γδT cells.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental: 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acute lymphoblastic leukemia treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic lymphoblastic leukemia with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Non-hodgkin lymphoma treated with chimeric antigen receptor modified γδT cells(Anti-CD19-CAR γδT) targeting CD19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anti-CD19-CAR γδT</intervention_name>
    <description>Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)</description>
    <arm_group_label>Experimental: 1</arm_group_label>
    <arm_group_label>Experimental: 2</arm_group_label>
    <arm_group_label>Experimental: 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Relapsed or refractory B cell derived acute lymphoblastic leukemia(ALL), chronic
             lymphoblastic leukemia(CLL) and non-hodgkin lymphoma.

          2. KPS&gt;60.

          3. Life expectancy&gt;3 months.

          4. Gender unlimited, age from 18 years to 70 years.

          5. CD19 expression must be detected on greater than 15% of the malignant cells by
             immunohistochemistry or greater than 30% by flow cytometry.

          6. Patients who have failed at least one line of a standard treatment.

          7. No serious mental disorder.

          8. Patients must have adequate cardiac function(no cardiac disease, LVEF≥40% ), adequate
             pulmonary function as indicated by room air oxygen saturation of &gt;94%, and adequate
             renal function(Cr≤133umol/L).

          9. No other serious diseases(autoimmune disease, immunodeficiency etc.).

         10. No other tumors.

         11. Patients volunteer to participate in the research.

         12. Patients with history of allogeneic stem cell transplantation are eligible if at least
             100 days post-transplant, if there is no evidence of active GVHD and no longer taking
             immunosuppressive agents for at least 30 days prior to infusion.

        Exclusion Criteria:

          1. KPS&lt;50.

          2. Patients are allergic to cytokines.

          3. Central nervous system leukemia within 28 days.

          4. Uncontrolled active infection.

          5. Acute or chronic GVHD.

          6. Treated with T cell inhibitor.

          7. Pregnancy and nursing females.

          8. HIV/HBV/HCV Infection.

          9. Other situations we think improper for the research.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li gangyi, master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Doing Biomedical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xie yanyun, master</last_name>
    <phone>+8615601041145</phone>
    <email>yanyun_xie@doingtimes.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li gangyi, master</last_name>
    <phone>+8613601204100</phone>
    <email>gangyi_li@doingtimes.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing DOING Biomedical Co., Ltd</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 12, 2016</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2016</study_first_posted>
  <last_update_submitted>September 1, 2017</last_update_submitted>
  <last_update_submitted_qc>September 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>CAR γδT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

